Aurobindo Pharma USA to Establish New R&D and Manufacturing Center in Durham, NC

Aurobindo Pharma USA, Inc. has officially announced the selection of Durham, NC as the location for their new R&D and manufacturing center.

Aurobindo USA

Aurobindo USA (photo –

Supported by incentives under the North Carolina Job Development Investment Grant (JDIG) program, and additional Durham economic development incentives, the company is investing over $31.7 million in a new state-of-the-art national headquarters for specialty pharmaceutical R&D.

The company expects to create 275 new R&D and pharma-manufacturing jobs in Durham. The company currently employs 14 scientists and workers in Raleigh. Their expanded operations will create a $17.1 million annual payroll impact for Durham and surrounding counties.

Dayton, NJ-based Aurobindo Pharma USA is a unit of Aurobindo Pharma Limited, headquartered in Hyderabad, India. The publicly-held parent company (BSE: AUROPHARMA) is recognized as one of the top 10 pharmaceutical companies (brand or generic) in terms of total prescriptions dispensed. Last year, Forbes Asia named Aurobindo Pharma to its “Fabulous 50” list. The company employs a worldwide workforce of 15,500.

Governor Pat McCrory said in a statement that “Our state is eager to partner with this global company as it embarks on its business objectives and grows its presence in North Carolina’s life sciences community.”

Dr. Ninad Deshpanday, President, R&D, Aurobindo Pharma USA, Inc., added that “We are very excited about our plans for expansion of our specialty pharma R&D and manufacturing in North Carolina, and are thankful to EDPNC, Durham City, Durham County and the State of North Carolina for supporting our decision.”

Apart from the Research Triangle site in Durham, the company also considered locating this new facility on land it owns at its headquarters in New Jersey.

In order to secure the project, North Carolina has awarded the company incentives under the JDIG program. Under the terms of the company’s JDIG, Aurobindo Pharma USA is eligible to receive up to $3.8 million in total reimbursements that will paid as 13 annual installments. Aurobindo Pharma USA’s North Carolina expansion could provide as much as $1.2 million in new funds for the state’s Utility Account to help finance economic infrastructure in less populated Tier 1 and Tier 2 counties.

Durham County and the City of Durham are additionally providing local incentives per job created, in addition to job training funding and support and usage of the NCWorks Career Center system for recruitment.

Apart from the City and County, NC Commerce, and the Economic Development Partnership of North Carolina (EDPNC), other partners who helped secure the project include the Greater Durham Chamber of Commerce and NC Biotechnology Center.

Leave a Reply

Your email address will not be published. Please enter your name, email and a comment.